Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: A review
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
At least 25-30% of patients with cancer and an even higher percentage of patients in an advanced phase of illness meet the criteria for a psychiatric diagnosis, including depression, anxiety, stress-related syndromes, adjustment disorders, sleep disorders and delirium. A number of studies have accumulated over the last 35 years on the use of psychotropic drugs as a pillar in the treatment of psychiatric disorders. Major advances in psycho-oncology research have also shown the efficacy of psychotropic drugs as adjuvant treatment of cancer-related symptoms, such as pain, hot flushes, pruritus, nausea and vomiting, fatigue, and cognitive impairment. The knowledge about pharmacokinetics and pharmacodynamics, clinical use, safety, side effects and efficacy of psychotropic drugs in cancer care is essential for an integrated and multidimensional approach to patients treated in different settings, including community-based centres, oncology, and palliative care. A search of the major databases (MEDLINE, Embase, PsycLIT, PsycINFO, the Cochrane Library) was conducted in order to summarize relevant data concerning the efficacy and safety of pharmacotherapy for cancer-related psychiatric disorders in cancer patients across the trajectory of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“Controversies regarding potentially fewer side effects, generally safer profi le and better tolerability of atypicals versus typicals are still not clarifi ed in psychiatric literature (Leucht et al., 2003, 2009, 2013).”
BackgroundMitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., & Meader, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70002-x · Cited by 2,449 · cited 1×
“…cancer patients in different clinical settings including oncology and haematology, meet the criteria for a psychiatric diagnosis, mainly depressive disorders, anxiety, and adjustment and stress-related disorders, across the trajectory of their disease (Mitchell et al., 2011; Singer et al., 2010).”
BackgroundSelf-citationSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · cited 1×
“Data are available about the use of SSRIs (e.g. paroxetine, sertraline) to prevent and/or to treat depression in cancer patients, specifi cally malignant melanoma patients, receiving high dose alphainterferon (Capuron et al., 2003; Musselman et al., 2001; Reddy et al., 2008).”
BackgroundInsomnia in the Context of Cancer: A Review of a Neglected Problem
Savard, J., & Morin, C. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.895 · Cited by 861
Interferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
Stahl, S. M. (2021) · doi:10.1017/9781108975292 · Cited by 480
Hypnotics' association with mortality or cancer: a matched cohort study
Kripke, D. F., Langer, R. D., & Kline, L. E. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-000850 · Cited by 408
Prevalence of mental health conditions in cancer patients in acute care—a meta-analysis
Singer, S., Das-Munshi, J., & Brähler, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp515 · Cited by 392 · cited 1×
“…cancer patients in different clinical settings including oncology and haematology, meet the criteria for a psychiatric diagnosis, mainly depressive disorders, anxiety, and adjustment and stress-related disorders, across the trajectory of their disease (Mitchell et al., 2011; Singer et al., 2010).”
BackgroundPsychiatric disorders in advanced cancer
Miovic, M., & Block, S. (2007) · Cancer · doi:10.1002/cncr.22980 · Cited by 376
Evidence‐based treatment of depression in patients with cancer
Li, M., Fitzgerald, P., & Rodin, G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7372 · Cited by 236 · cited 1×
“Major depression, as one of the most signifi cant psychiatric complication of cancer, has been shown to be effectively treated, and algorithms and guidelines are today available in clinical settings, both in oncology and palliative care (Li et al., 2012; Rodin et al., 2007).”
BackgroundAntidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205 · cited 1×
“Because of the possible effects of both SSRIs and SNRIs in determining sexual dysfunctions, prescribing decisions in cancer patients should be based on a careful assessment of the benefi ts and risks of therapy on an individual basis (Montgomery et al., 2002).”
BackgroundEfficacy and safety of mianserin in the treatment of depression of women with cancer
Costa, D., Mogos, I., & Toma, T. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb08081.x · Cited by 202 · cited 1×
“…trials (RCTs) in cancer patients have shown the effi - cacy of several ADs, especially second and third generation ADs, including mianserin (Costa et al., 1985; van Heeringen & Zivkov, 1996), fl uoxetine (Holland et al., 1998; Razavi et al., 1996), paroxetine (Amodeo et al., 2012; Pae et…”
BackgroundDezentjé, V. O., van Blijderveen, N. J. C., Gelderblom, H., Putter, H., van Herk-Sukel, M. P. P., Casparie, M. K., Egberts, A. C. G., Nortier, J. W. R., & Guchelaar, H.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0894 · Cited by 163
The prevalence and pharmacotherapy of depression in cancer patients
Ng, C. G., Boks, M. P. M., Zainal, N. Z., & de Wit, N. J. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.07.034 · Cited by 138 · cited 1×
“Depression is one of the most common disorders in cancer patients and updated research has confi rmed the increase rate of ADs prescribed for cancer patients, with the intent of addressing symptoms of depression (Ng et al., 2011; Grassi et al., 2011).”
BackgroundOkamura, M., Akizuki, N., Nakano, T., Shimizu, K., Ito, T., Akechi, T., & Uchitomi, Y. (2008) · Psycho-Oncology · doi:10.1002/pon.1213 · Cited by 46 · cited 1×
“Algorithms and guidelines are today available for the most effective treatment of depression in cancer care (Okamura et al., 2008; Rodin et al., 2007), including palliative care (Rayner et al., 2011a; 2011b).”
Olanzapine for nausea and vomiting.
Licup, N., & Baumrucker, S. (2010) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909110369532 · Cited by 23 · cited 1×
“Apart from the use of both phenothiazines and haloperidol, more recently atypical APs, especially olanzapine, have been demonstrated their effi cacy and safety (Ang et al., 2010; Licup, 2010).”
Background
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“Antidepressants and, less frequently, benzodiazepines are used to treat depressed mood and anxiety in cancer patients, although evidence suggesting efficacy is limited and conflicting, and benzodiazepines are generally only recommended for short-term use because of side effects and withdrawal (Grassi et al., 2014; Ost…”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline
Grassi, L., Caruso, R., Riba, M. B., Lloyd-Williams, M., Kissane, D., Rodin, G., McFarland, D., Campos-Ródenas, R., Zachariae, R., Santini, D., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101155 · Cited by 316
Self-citationManagement of Delirium in Palliative Care: a Review
Grassi, L., Caraceni, A., Mitchell, A. J., Nanni, M. G., Berardi, M. A., Caruso, R., & Riba, M. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0550-8 · Cited by 300
Self-citation
Metadata
- Authors
- Grassi, L., Caruso, R., Hammelef, K., Nanni, M. G., & Riba, M.
- Venue
- International Review of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2014-02
- Volume
- 26
- Issue
- 1
- Pages
- 44-62
- ISSN
- 0954-0261 (ISSN-L)
- 1369-1627
- OpenAlex
- W2082535915
- Cited by
- 101
- References
- 18
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.